Spectrum of Atazanavir‐Selected Protease Inhibitor‐Resistance Mutations

Funding Information: Conflicts of Interest: A.S. received research grants from Gilead Sciences, and personal fees for ad‐ visory boards from Gilead Sciences, MSD, and ViiV Healthcare, all outside the present work. M.Z. received research grants from Gilead Sciences, MSD, Theratechnologies and ViiV He...

Full description

Bibliographic Details
Main Author: the EuResist Network Study Group (author)
Other Authors: Abecasis, Ana B. (author)
Format: article
Language:eng
Published: 2022
Subjects:
antiviral therapy
ataza-navir
drug resistance
HIV‐1
mutation
protease
protease inhibitor
Immunology and Allergy
Molecular Biology
Immunology and Microbiology(all)
Microbiology (medical)
Infectious Diseases
SDG 3 - Good Health and Well-being
Online Access:http://hdl.handle.net/10362/140466
Country:Portugal
Oai:oai:run.unl.pt:10362/140466

Internet

http://hdl.handle.net/10362/140466

Similar Items